Deutsche Bank Ag\ Entrada Therapeutics, Inc. Transaction History
Deutsche Bank Ag\
- $248 Billion
- Q4 2024
A detailed history of Deutsche Bank Ag\ transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 21,740 shares of TRDA stock, worth $292,185. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,740
Previous 13,983
55.47%
Holding current value
$292,185
Previous $223,000
68.16%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding TRDA
# of Institutions
105Shares Held
29.1MCall Options Held
36.5KPut Options Held
5.1K-
Baker Bros. Advisors LP New York, NY4.87MShares$65.4 Million0.93% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$59.2 Million33.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$58.9 Million60.89% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.9MShares$39 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.08MShares$28 Million0.02% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $422M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...